Fig. 1.

Overview of “Phase 0 clinical trial” approach to modelling DOC. Multimodal neuroimaging data from each individual patient are combined into a patient-specific “fingerprint”, and subsequently used (possibly together with normative data from the population) to inform a personalised brain model for each patient. For a given patient, the effects of different treatments can then be simulated in silico with their individualised model, to obtain insights about promising treatment avenues.